Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection.

Jesper JarkvistClara SalehiCem AkinTheo Gulen

Published in: Allergy (2019)

Both safety and efficacy of VIT in cMCD patients were slightly reduced than controls. Severe ARs were rare. The elevated IgG4 levels may be a biomarker for efficacy of VIT in cMCD patients, as it correlates with protection from re-stings.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis